



Pharmaceutical Management Agency

14 July 2004

Level 14, Cigna House,
40 Mercer Street, PO Box 10-254
Wellington 6001, New Zealand
Phone 64 4 460 4990
Fax 64 4 460 4995
www.pharmac.govt.nz

To All Interested Parties*By facsimile (1 page)***Provisional Agreement regarding the listing of colchicine (Colgout)**

PHARMAC has entered into a provisional agreement with Anspec Pty Limited for the future listing of its brand of colchicine (Colgout).

The main features of this proposal are:

- Anspec Pty Limited and PHARMAC have entered into a provisional agreement for the listing of colchicine 500 µg tablets, subject to the Colgout brand obtaining market approval prior to listing.
- If the Colgout brand obtains market approval and is listed, no other brand of colchicine would be listed with sole supply status for two years from the date of listing, nor would reference pricing be applied to Colgout for two years from the date of listing.
- Colgout would be listed in Section B and Section H of the Pharmaceutical Schedule at the price and subsidy outlined in the table below:

Pharmaceutical	Brand	Presentation	Pack Size	Proposed price and subsidy
Colchicine	Colgout	500 µg tablets	100 tablets	\$ 9.60

Price and subsidy listed is ex-manufacturer, exclusive of GST

If you have comments to make on this proposal and would like those comments to be considered by the PHARMAC Board (or the Chief Executive) please send them to Sophie Dalziel at PHARMAC by **5 p.m. on Wednesday, 28 July 2004**. The Board (or the Chief Executive) will consider all comments that are submitted by this date.

Yours sincerely

Wayne McNee
Chief Executive